3 Pharmaceutical Formulations Maker, Molecular Diagnostics Company and Enterprise Software Company Stocks With a Strong Future Roadmap: Granules India, Molbio Diagnostics and Newgen Software Technologies
- November 12, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Granules India, Molbio Diagnostics and Newgen Software Technologies: ROE of 11.7% to 18.7% and FY22 to FY26 revenue CAGR of 9.2% to 19.4%. Prices as of 11 Nov 2026.
Quick Answer
The three pharma, molecular testing and software stocks to watch are Granules India, Molbio Diagnostics and Newgen Software Technologies. Their return on equity ranges from 11.7% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 19.4%. Newgen Software Technologies leads on both return on equity at 18.7% and revenue growth at 19.4% a year. Prices are based on the 11 November 2026 close, and this article is educational, not investment advice.
Pharma, molecular testing and software stocks give investors a way to track businesses that sit close to everyday demand in India. Granules India, Molbio Diagnostics and Newgen Software Technologies cover a pharmaceutical formulations maker, a molecular diagnostics company and an enterprise software company.
This list covers three pharma, molecular testing and software stocks with complete current figures: Granules India, Molbio Diagnostics and Newgen Software Technologies. Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pharma, Molecular Testing and Software Stocks?
Pharma, molecular testing and software stocks are listed companies that make tablets, capsules and active ingredients for global drug firms, build molecular diagnostic test kits and instruments, and sell content, workflow and process automation software to banks, governments and large firms. Their earnings depend on prescription demand, test volumes and software contracts.
Pharma, Molecular Testing and Software Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Granules India | 799.25 | 22,002 | 33.2 | 36.0 | 11.7 | 0.30 |
| Molbio Diagnostics | 1,318.6 | 16,605 | 101.2 | 59.6 | 14.2 | 0.38 |
| Newgen Software Technologies | 440.45 | 6,835 | 21.8 | 17.5 | 18.7 | 0.02 |
On valuation, Granules India trades at a P/E below the industry P/E, while Molbio Diagnostics and Newgen Software Technologies trade above it, which reflects the growth the market already expects. Readers comparing pharma, molecular testing and software stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Pharma, Molecular Testing and Software Stocks Have a Strong Roadmap in India?
Pharma, molecular testing and software stocks have a strong roadmap in India because steady global demand for generic medicines, wider use of molecular testing and growing digitisation of paper based work keep widening the market for these companies.
- Pharma. Generic medicines reach more markets.
- Molecular diagnostics. Doctors rely more on precise tests.
- Enterprise software. Large firms automate document workflows.
Why Granules India Features Among These Pharma, Molecular Testing and Software Stocks
Among the pharma, molecular testing and software stocks on this list, Granules India is a Hyderabad-based pharmaceutical manufacturer that makes active ingredients, intermediates and finished dosage forms, with a strong position in paracetamol, metformin and ibuprofen.
Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%.
In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0.
Roadmap: The company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.
What to watch: Monitor new product approvals and the share of finished dosages in total sales.
Why Molbio Diagnostics Features Among These Pharma, Molecular Testing and Software Stocks
Among the medicine, rapid test and document tech shares on this list, Molbio Diagnostics, based in Goa, develops the Truenat platform, a portable molecular diagnostics system that delivers lab-grade PCR results at the point of care, with strong use in tuberculosis testing.
Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%.
The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6.
Roadmap: Its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
What to watch: Order timing from public health programmes can be lumpy, so look at annual rather than single-quarter trends.
Why Newgen Software Technologies Features Among These Pharma, Molecular Testing and Software Stocks
Among the three companies on this list, Newgen Software Technologies, based in Delhi, offers low-code platforms for content management, process automation and customer engagement to banks, insurers and governments.
The company has a return on equity of 18.7%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 6,835 crore. The stock trades at a P/E of 21.8, above the industry P/E of 17.5.
Revenue rose from Rs 809 crore in FY22 to Rs 1,641 crore in FY26, a compound annual growth rate of 19.4%. Net profit grew from Rs 164 crore in FY22 to Rs 301 crore in FY26, which works out to a compound annual growth rate of 16.3%. In the June 2026 quarter, revenue grew 12.3% year on year to Rs 393 crore, while net profit rose 26.3% to Rs 62.8 crore.
Roadmap: Digital transformation at banks and public sector organisations, plus new artificial intelligence features on its platform, widen its addressable market. A growing share of recurring licence and cloud revenue improves predictability.
What to watch: Monitor deal wins in the banking sector and the growth of recurring revenue.
Granules India vs Molbio Diagnostics vs Newgen Software Technologies on Key Financials
The table below sets the three pharma, molecular testing and software stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Granules India | 3,783 | 5,386 | 9.2% | 595 | 11.0% |
| Molbio Diagnostics | 782 | 1,455 | 16.8% | 164 | 11.3% |
| Newgen Software Technologies | 809 | 1,641 | 19.4% | 301 | 18.3% |
Newgen Software Technologies posts the highest return on equity in this group at 18.7%. Granules India has the largest FY26 revenue at Rs 5,386 crore, and Newgen Software Technologies shows the fastest revenue growth with a 19.4% compound annual rate. A useful habit with pharma, molecular testing and software stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Pharma, Molecular Testing and Software Stocks
Every theme carries risks that deserve a check before any decision. For these pharma, molecular testing and software stocks, the main points are: Long-term medicine, rapid test and document tech shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Pricing pressure. Generic prices can change by market.
- Test volumes. Footfall and test mix can vary with seasons.
- Client spending. Technology budgets can vary with global conditions.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pharma, molecular testing and software stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pharma, Molecular Testing and Software Stocks
Pharma, molecular testing and software stocks work best when investors track growth, valuation and return on equity side by side. Granules India, Molbio Diagnostics and Newgen Software Technologies each have a clear plan to grow. Based on the 11 November 2026 close, Granules India trades at Rs 799.25, Molbio Diagnostics at Rs 1,318.6 and Newgen Software Technologies at Rs 440.45. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these pharma, molecular testing and software stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track pharma, molecular testing and software stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pharma, molecular testing and software stocks?
Ans. Pharma, molecular testing and software stocks are listed companies that make tablets, capsules and active ingredients for global drug firms, build molecular diagnostic test kits and instruments, and sell content, workflow and process automation software to banks, governments and large firms. Their earnings depend on prescription demand, test volumes and software contracts. This list looks at three of them, Granules India, Molbio Diagnostics and Newgen Software Technologies, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.
Which pharma, molecular testing and software stocks are covered in this list?
Ans. This list covers Granules India, Molbio Diagnostics and Newgen Software Technologies. Based on the 11 November 2026 close, Granules India traded at Rs 799.25, Molbio Diagnostics at Rs 1,318.6 and Newgen Software Technologies at Rs 440.45. Their return on equity ranges from 11.7% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 19.4%.
Why do pharma, molecular testing and software stocks have a strong future roadmap in India?
Ans. Pharma, molecular testing and software stocks have a strong roadmap in India because steady global demand for generic medicines, wider use of molecular testing and growing digitisation of paper based work keep widening the market for these companies. The main drivers are as follows. Pharma. Generic medicines reach more markets. Molecular diagnostics. Doctors rely more on precise tests. Enterprise software. Large firms automate document workflows. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Granules India performed financially?
Ans. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.
How has Molbio Diagnostics performed financially?
Ans. Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6. Looking ahead, its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
How has Newgen Software Technologies performed financially?
Ans. Revenue rose from Rs 809 crore in FY22 to Rs 1,641 crore in FY26, a compound annual growth rate of 19.4%. Net profit grew from Rs 164 crore in FY22 to Rs 301 crore in FY26, which works out to a compound annual growth rate of 16.3%. In the June 2026 quarter, revenue grew 12.3% year on year to Rs 393 crore, while net profit rose 26.3% to Rs 62.8 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 6,835 crore. The stock trades at a P/E of 21.8, above the industry P/E of 17.5. Looking ahead, digital transformation at banks and public sector organisations, plus new artificial intelligence features on its platform, widen its addressable market. A growing share of recurring licence and cloud revenue improves predictability.
What risks should investors check before buying pharma, molecular testing and software stocks?
Ans. Investors should check a few risks before buying pharma, molecular testing and software stocks. Pricing pressure. Generic prices can change by market. Test volumes. Footfall and test mix can vary with seasons. Client spending. Technology budgets can vary with global conditions. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pharma, molecular testing and software stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
